Authors
Mavin Macauley, Kieren G Hollingsworth, Fiona E Smith, Peter E Thelwall, Ahmad Al-Mrabeh, Anja Schweizer, James E Foley, Roy Taylor
Publication date
2015/4/1
Journal
The Journal of Clinical Endocrinology & Metabolism
Volume
100
Issue
4
Pages
1578-1585
Publisher
Oxford University Press
Description
Context
Although dipeptidyl-peptidase-4 inhibitors exert their major action via an incretin mechanism, a favorable effect of vildagliptin on lipid metabolism remains unexplained.
Objective
The objective was to examine hepatic triglyceride levels and insulin sensitivity on vildagliptin.
Design
This was a 6-month, randomized, double-blind, placebo-controlled trial.
Setting
This was an outpatient study at a university clinical research center.
Patients
Individuals with type 2 diabetes (n = 44) and glycated hemoglobin ≤7.6% on stable metformin therapy were included.
Intervention
Intervention was vildagliptin 50 mg twice a day or placebo over 6 months.
Main Outcome Measures
Main outcome measures were hepatic triglyceride levels and insulin sensitivity.
Results …
Scholar articles
M Macauley, KG Hollingsworth, FE Smith, PE Thelwall… - The Journal of Clinical Endocrinology & Metabolism, 2015